Purpose: To evaluate the efficacy and toxicity of vinorelbine in a phase II study in patients with progressive metastatic androgen-independent prostate cancer.
Introduction
Prostate cancer is the most common malignancy in men and the second cause of death in men after lung cancer [1] . Fifty to 60% of patients have locally advanced cancer (stage C and Dl) or metastatic disease (stage D2) at the time of diagnosis. Androgen deprivation is the standard therapy for newly diagnosed metastatic cancer. It can be achieved in several ways and produces symptomatic improvement in 60 to 70% of patients but results in only a small prolongation in both progressionfree survival and overall survival [2] . Second line hormonal manipulation when patients relapse has been extensively studied. Treatment with prednisone [3] , ketoconazole [4] , aminoglutethimide with hydrocortisone and anti-androgens such as cyproterone acetate or flutamide, result in 20% response rate over no more than six months [5] [6] [7] . Chemotherapy has been tested in patients with hormone-unresponsive disease. Chemotherapeutic agents have shown a response rate ranging from 15 to 30% without any survival improvement [8, 9] . Although preliminary results of phase II trials with suramin yielded a response rate of 30% to 40%, the incidence of severe side effects exceeded 80% [10, 11] . Proposal of other chemotherapeutic agents is an urgent need as elderly patients are the age group at greatest risk for prostatic cancer and this age group has poor tolerance for chemotherapy. Vinorelbine, which is devoid of severe toxicity, may be an option. Vinorelbine is a new semisynthetic vinca-alkaloid derivative and exhibits anti-microtubular activity. Vinorelbine is a highly effective agent in the treatment of non-small cell lung cancer [12, 13] and in hormone-dependent tumours such as breast cancer [14] . We report here the results of a phase II study of vinorelbine in 47 patients with progressive androgenindependent prostate cancer (AIPC).
Patients and methods

Patient characteristics
Eligible patients were required to have a histologic diagnosis of adenocarcinoma of the prostate with progressive disease after at least one line of standard hormonal therapy. All patients previously treated with an anti-androgen were required to undergo anti-androgen withdrawal. Patients were required to be off all anti-androgens for at least four weeks, with further evidence of disease progression after cessation of the anti-androgen. To control for the effects of androgen ablation, luteinizing hormone-releasing hormone therapy was maintained. All patients had serum testosterone levels < 50 ng/ml at the time of entry. Progression of the disease after androgen ablation, was defined by at least one of three criteria: (1) two consecutive increased PSA measurements taken at least two weeks apart and PSA value greater than 10 ng/ml for patients with bone metastases only; (2) a greater than 25% increase in bidimensionally measurable soft tissue metastases or in the area of bone involvement; (3) the appearance of new foci on a bone scan. All patients gave written informed consent in accordance with institutional guidelines.
Other criteria included a minimum life expectancy of > 3 months and Eastern Cooperative Oncology Group (ECOG) performance status (PS) < 2; age less than 85 years; no prior chemotherapy including estramustine phosphate; adequate bone marrow reserve, defined as a granulocyte count ^ 1500/ul. haemoglobin > 9 g/dl and platelet count > 100,000/(41, serum aspartate aminotransferase level ^ 2 5 x the institutional upper limit of normal, bilimbin level <1.5x the institutional upper limit of normal, and creatinine level <2x the institutional upper limit of normal. Patients had to have recovered for at least four weeks after radiation therapy with no radioisotope therapy within eight weeks of entry into the study No herbal medicine was allowed during (he study.
Toxicity and response criteria
Toxicity was graded according to the CALBG Expanded Common Toxicity Criteria. Therapeutic effect was assessed using criteria for measurable disease, if present, and for change in serum PSA. Due<to the difficulty of analysing efficacy of criteria, taking into account serum PSA changes, tumour response and clinical benefit, it was decided to separate these three parameters for response criteria. Most of the patients could not be evaluated for all three criteria. PSA was analysed by percentage decrease for each patient: reduction by at least 80% on two consecutive evaluations more than two weeks apart; reduction by at least ^ 50% on two separate occasions more than two weeks apart, stable disease was defined by a decrease in PSA < 50% [15] . Additionally, in patients with bidimensionally measurable metastases, objective response was evaluated according to World Health Organisation criteria. Clinical benefit was defined as beneficial subjective response (improvement) as follows : positive response in one category (reduction of the pain score by at least one score and/or performance status improved by at least one score) or at least stable assessment in the two categories (pain score and performance status). The clinical benefit was evaluated at the same timepoint as tumour assessment (eight weeks). Bone pain was evaluated by using the following score: 0 = no pain or requirement for analgesics, I = mild pain, occasional non-narcotic analgesic use; 2 = moderate pain, regular non-narcotic analgesic use; 3 = severe pain, occasional narcotic analgesic use, 4 = uncontrollable pain, regular narcotic analgesic use.
Statistical analysis
Since the writing of the protocol, efficacy criteria assessment of prostate cancer has evolved, the testing procedure described by Fleming and based on NPCP criteria is no longer valid. In the present study, PSA response was considered as the principal criterion of efficacy. Survival times were established from the date the patient was registered into the study until time of death or the last follow-up. Survival curves were calculated by the Kaplan-Meier method. Quality of life data from the EORTC QLQ-C30 questionnaire were analysed using descriptive statistics to report items such as mean, median, and standard deviations of QOL scores. Paired /-tests were used to compare means of QOL measures at each time point.
Evaluation
Pre-treatment evaluation included a medical history, weight, assessment of ECOG performance status, physical examination, complete blood cell count, serum chemistry profile, PSA measurement, chest X-ray, bone scan, computed tomographic (CT) scan of the abdomen and pelvis, and ECG Complete blood cell counts were monitored weekly and chemistry profiles and PSA determinations were repeated every three weeks on day 1 of each treatment cycle. CT scans to assess measurable lesions were obtained every 8 weeks and bone scans were performed every 12 weeks. Quality of life assessment (EORTC QLQ-C30 questionnaire) was performed at baseline and was repeated after the first 8 weeks and every 12 weeks thereafter.
Treatment regimen
All treatment programs were administered on an outpatient basis. Vinorelbine was administered at a dose of 25 mg/m 2 weekly. Each patient was given vinorelbine for at least eight weeks unless progression or unacceptable toxicity occurred. Treatment was discontinued in case of the patient's refusal, acute life-threatening grade 3 or 4 toxicities according to CALBG Expanded Common Toxicity Criteria, or progression of disease. No other hormonal, corticoid therapy or diphosphonates were allowed during treatment. Administration of growth factor was discouraged.
Results
Patient characteristics
From December 1994 to September 1996, 47 men were enrolled into this phase II study. There were four noneligible patients (three patients had prior estramustinebased therapy, one patient had adenocarcinoma not histologically documented). The pre-treatment characteristics of the 43 eligible patients are listed in Table 1 . The median age was 69.6 years and 72% of patients had a performance status of 0 or 1. The median time from diagnosis of prostatic cancer to chemotherapy was 31.3 months (range 1 week-Ill months). The majority of patients had complete androgen blockade with medical castration (70%) or surgical castration with or without anti-androgen in 27% of patients. The majority of patients (81%) had received one prior line of hormonal manipulation.
Thirty-three patients were assessable for tumour response including 3 patients for bidimensionally measurable metastases (9%), 36 patients were assessable for evaluable for PSA response. Among these patients, four of them had a greater than 80% decrease in PSA level. The serum PSA nadir for these 6 patients was reached after a median number of 11 administrations (range 7-13). Stabilisation was reported in 24 patients (67%i) with evaluable PSA. Efficacy results based on the bidimensionally measurable tumour response showed that two patients out of three had partial responses but these were unconfirmed. No change in disease was reported in 23 patients out of 33 (49%). One of them had a concomitant decrease in PSA of $= 50% in comparison with pre-treatment level.
Thirty patients had symptomatic bone pain and required narcotic (seven patients) or non-narcotic analgesics at the time of study entry. Among these seven patients, three of them (43%) discontinued their use of narcotic analgesics for a mean duration of seven weeks (range 1-20 weeks). Clinical benefit from vinorelbine treatment was achieved in 15 patients out of 21 (71%) of the assessable patients and 32% of the intent to treat analysis population). Among the six patients who experienced a PSA response, two patients had an improvement of clinical benefit. Performance status and pain score remained stable in three patients and were not reported in one patient. Table 2 summarizes the efficacy results.
Forty-five patients were assessed for quality of life at inclusion. During treatment, 28 patients underwent the first evaluation (62%) and 10 patients two evaluations (22%). Considering that the time interval between the first two evaluations was 8 weeks and then 12 weeks, the number of questionnaires filled in was insufficient to allow any statistical analysis to be performed.
Progression-free survival and overall survival curves are shown in Figures 1 and 2 . The median time to progression of disease for the entire group was 12 weeks. The estimated median survival time for all patients was 41 weeks (95% confidence interval: 29-70 weeks). PSA response was associated with longer progression-free survival. 2 ) and median relative dose intensity was 76% (range 48%-105%). Delay in vinorelbine administration was mainly due to haematotoxicity and occurred in 73% of patients and for 35% of administrations.
Twenty-three patients experienced grade 3-4 CALGB toxicity for neutrophils (Table 3 ) but only one developed febrile neutropenia requiring hospitalisation. Analysis of haematological tolerance per administration showed that CALGB grade 3-4 leucopenia and neutropenia were reported in 9% and 15% of the administrations, respectively. Thrombocytopenia was mild, with only seven patients experiencing grade 1 toxicity. Anaemia (grade 3-4) was found in six patients. Three patients developed deep vein thrombosis (two lower limb thrombo-phlebitis and one medial jugular vein on subclavian catheter) while on therapy. One patient had a bilateral pulmonary embolism following the lower limb thrombo-phlebitis. All three patients were successfully treated with anticoagulants and continued treatment without other major toxicities. Mild to moderate nausea was common, although vomiting was relatively rare. No case of treatment discontinuation because of nausea was reported. Neurotoxicity, essentially peripheral, was of low incidence (grade 1: 13%) and mainly affected deep tendon reflexes. There were no therapy-related deaths. Only transient (grade [3] [4] changes in the liver enzymes were seen in a small proportion of administrations (alkaline phosphatases: 10%).
Discussion
Preliminary in vitro and in vivo evidence demonstrates that vinca-alkaloids may inhibit prostate cancer growth by interfering with the polymerization of tubulin [16, 17] . Vinblastine has shown a 21% response rate in one study when administered as a continuous infusion [18] , Recently, in a phase III study, vinblastine alone showed a > 50% PSA decline sustained for at least three successive monthly measurements in 3.2% of patients and median survival was 9.2 months [19] . Vinorelbine is a newer vinca alkaloid with less neurotoxicity and is differentiated from other analogs by its pharmacokinetics profile: long terminal half-life, high plasma clearance and very large volume of distribution. A recent report by Fields-Jones et al., showed in 37 evaluable patients with AIPC a 39% clinical benefit assessed by analgesic consumption and performance status [20] . The present study demonstrates the activity of vinorelbine in AIPC in terms of tumour response, PSA decline and clinical benefit criteria. Of the 47 patients included in the study, 6 (17%) had a decline greater than 50% in measured PSA values and in 23 (49%) no tumour change was observed. The median duration of biologic response was 2.7 months. Clinical benefit from vinorelbine was achieved in 15 of the 21 evaluable patients (32%). This clinical benefit of vinorelbine is roughly similar to the two Canadian studies on mitoxantrone and prednisone which gave palliative response in 36% [21] and 29% [22] , respectively.
The median survival of 10.2 months observed in this trial is similar to that seen in other phase II trials in AIPC [23] .
A PSA decrease of 50% or more from the baseline value has been reported to be a surrogate biologic end point for response [24] . In our study, in two patients who experienced a significant reduction of pain, a biologic response was observed as well. Moreover, PSA response was associated with longer progression-free survival.
Treatment was given on an outpatient basis and was well tolerated. Granulocytopenia was the main toxicity, requiring delays in treatment and/or reductions in vinorelbine dosing in a quarter of the patients during the first two administrations. The actual dose-intensity tolerated by the majority of patients was 19 mg/m 2 /week or 76% of the planned dose-intensity. Only one episode of febrile neutropenia occurred and required hospitalisation. There were no therapy-related deaths.
More studies are warranted to evaluate the benefit of vinorelbine in association with corticosteroids or chemotherapy, as suggested by a phase II study of vinorelbine and estramustine phosphate [25] . A large European phase III study is ongoing to evaluate the clinical benefit of hydrocortisone and aminoglutethimide plus or minus vinorelbine.
Conclusion
Overall results of this phase II study suggest activity of vinorelbine in elderly patients with AIPC. Vinorelbine acts on PSA response and clinical benefit based on improvement of performance status and/or bone pain. These results provide data for future investigation of vinorelbine in association with other microtubule inhibitors or corticosteroids in phase 11 -III trials.
